Eyeworld CME Supplements

EW_APR 2016 Supported by unrestricted educational grants from Allergan, Shire, TearLab, and TearScience

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/660868

Contents of this Issue

Navigation

Page 0 of 7

continued on page 2 patient. Moreover, we hope these assessments will help us diagnose this condition even before symptoms develop. Effects of OSD Because the tear film is the first refractive surface that light en- counters, an unstable tear film A lthough the prevalence of dry eye has been reported to range from 8–34%, it tends to be under recognized and under diagnosed (Figure 1). 1,2 Ocular surface health is crit- ically important to vision quali- ty—particularly after cataract and refractive surgery. Historically, dry eye disease (DED) and ocular surface disease (OSD) were not mainstream topics because our understanding of the pathophys- iology of the disease process was limited, as were our diagnostic and treatment modalities. We hope our new paradigm of point-of-care testing will drive awareness of the importance of DED and OSD and how they relate to the presurgical Point-of-care diagnostics will aid ophthalmologists in the early diagnosis of ocular surface disease by Terry Kim, MD " New point-of-care tests can help identify DED or OSD signs so we can identify cases early and treat them proactively. " –Terry Kim, MD Terry Kim, MD This monograph is part of a year-long curriculum focused on treatment of ocular surface disease and management. Supported by unrestricted educational grants from Allergan, Shire, TearLab, and TearScience Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Cataract & Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Identify the true impact of a dysfunctional ocular surface on cataract and refractive outcomes, identify the consequences that accompany an unstable tear film, and discuss the presentation of symptomatic vs. asymptomatic OSD • Describe the objective evidence supporting the use of new OSD diagnostic tools, including correlation of symptoms, predictive power, and relationship to outcomes, and develop strategies for incorporating new diagnostic tools into clinical practice, including: inclusion in point-of- care and preoperative testing, use of diagnostic information to guide treatment, and utilization of diagnostics to follow success of interventions or treatment Designation Statement The American Society of Cataract & Refractive Sur- gery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/1R8LNc7 to review content and download the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard Internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through September 31, 2016. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Adminis- tration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703-591-2220. Financial Interest Disclosures Kenneth Beckman, MD, FACS, has received a re- tainer, ad hoc fees or other consulting income from Allergan, Rapid Pathogen Screening, and TearLab. Alice T. Epitropoulos, MD, is a member of the speakers bureaus of: Allergan, Bausch + Lomb, NovaBay, PRN, Shire Pharmaceuticals, TearLab, and TearScience. She has received research funding from Bausch + Lomb, Ocular Therapeutix, PRN, and TearLab. Dr. Epitropoulos has received travel expense reimbursement from Bausch + Lomb and TearScience, and earns a royalty or derives other financial gain from Eye Care & Cure. Terry Kim, MD, has an investment interest in and has received a retainer, ad hoc fees, or other consulting income from Ocular Therapeutix Inc. and Omeros Corporation. He has received a retainer, ad hoc fees, or other consulting income from and is a member of the speakers bureau of Alcon Laboratories and Bausch + Lomb. Dr. Kim has received a retainer, ad hoc fees, or other consulting income from: Acuity Advisors, Acucela Inc., Allergan, CoDa Therapeutics, Foresight Biotherapeutics, Kala Pharmaceuticals, NovaBay Pharmaceuticals, Oculeve Inc., Ocular Systems Inc., PowerVision Inc., Presbyopia Therapies, Shire, Stealth BioTherapeutics, TearLab, and TearScience. Cynthia Matossian, MD, FACS, has an investment interest in, has received a retainer, ad hoc fees, or other consulting income from, and is a member of the speakers bureau of Physician Recommended Nutriceuticals. She receives royalties or derives other financial gain from, has an investment interest in, and is a member of the speakers bureau of Progressive Tech Training LLC. Dr. Matossian has an investment interest in and is a member of the speakers bureau of CheckedUp.com and Strathspey Crown LLC. She is a member of the speakers bureau of: Abbott Medical Optics, Alcon Laboratories, Allergan, Alphaeon, Bausch + Lomb, Imprimis Pharmaceuticals, i-Optics, Lenstec, Marco, Ocular Therapeutix Inc., Omeros Corporation, Rapid Pathogen Screening, Shire, and TearLab. Christopher E. Starr, MD, has an investment interest in, has received a retainer, ad hoc fees or other consulting income from, and is a member of the speakers bureau of TearLab. He has received a retainer, ad hoc fees or other consulting income from and is a member of the speakers bureaus of Allergan and Bausch + Lomb. Dr. Starr is a member of the speakers bureau of Alcon Laboratories and has received a retainer, ad hoc fees or other con- sulting income from GlassesOff and Shire. He has received a retainer, ad hoc fees or other consulting income and research funding from Rapid Pathogen Screening. Staff members: Kristen Covington, Laura Johnson, and Erin Schallhorn have no ophthalmic-related financial interests. 2016 Ocular Surface Disease The impact of ocular surface dysfunction on surgical outcomes: Evidence-based insights on diagnostic tools to guide treatments Supplement to EyeWorld April 2016 365 Curriculum The impact of a dysfunctional ocular surface on cataract and refractive outcomes reduces vision quality and ad- versely affects preop testing and postop vision quality. Epitropoulos et al. showed significant variation in average K readings and resulting IOL power calculations in patients with elevated tear osmolarity. 3 Click to read and claim CME credit

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW_APR 2016 Supported by unrestricted educational grants from Allergan, Shire, TearLab, and TearScience